help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1894
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/7/4287    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maiti, K.
Right arrow Articles by Seong, J. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maiti, K.
Right arrow Articles by Seong, J. Y.
Related Collections
Right arrow Endocrine Oncology
Right arrow Male Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 7 4287-4298
Copyright © 2005 by The Endocrine Society

Differential Effects of Gonadotropin-Releasing Hormone (GnRH)-I and GnRH-II on Prostate Cancer Cell Signaling and Death

Kaushik Maiti, Da Young Oh, Jung Sun Moon, Sujata Acharjee, Jian Hua Li, Dong Gyu Bai, Hee-Sae Park, Keesook Lee, Young Chul Lee, Neon Chul Jung, Kyungjin Kim, Hubert Vaudry, Hyuk Bang Kwon and Jae Young Seong

Hormone Research Center (K.M., D.Y.O., J.S.M., S.A., J.H.L., D.G.B., H.-S.P., K.L., Y.C.L., H.B.K., J.Y.S.) and School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea; Neurogenex Co. Ltd. (N.C.J.), Biotechnology Incubating Center Golden Helix, Seoul National University, Seoul 151-744, Republic of Korea; School of Biological Sciences (K.K.), Seoul National University, Seoul 151-742, Republic of Korea; Institut National de la Santé et de la Recherche Médicale U413, Laboratory of Cellular and Molecular Neuroendocrinology (H.V.), European Institute for Peptide Research, University of Rouen, 76821 Mont-Saint-Aignan, France; and Laboratory of G Protein Coupled Receptors (J.Y.S.), Korea University College of Medicine, Seoul 136-705, Republic of Korea

Address all correspondence and requests for reprints to: Jae Young Seong, Ph.D., Laboratory of G Protein Coupled Receptors, Korea University College of Medicine, Seoul 136-705, Republic of Korea. E-mail: jyseong{at}korea.ac.kr; or Hyuk Bang Kwon, Ph.D., Hormone Research Center and School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea. E-mail: kwnohb{at}chonnam.ac.kr.

Context: GnRH is known to directly regulate prostate cancer cell proliferation, but the precise mechanism of action of the peptide is still under investigation.

Objective: This study demonstrates differential effects of GnRH-I and GnRH-II on androgen-independent human prostate cancer cells.

Results: Both GnRH-I and GnRH-II increased the intracellular Ca2+ concentration ([Ca2+]i) either through Ca2+ influx from external Ca2+ source or via mobilization of Ca2+ from internal Ca2+ stores. Interestingly, the [Ca2+]i increase was mediated by activation of the ryanodine receptor but not the inositol trisphosphate receptor. Trptorelix-1, a novel GnRH-II antagonist but not cetrorelix, a classical GnRH-I antagonist, completely inhibited the GnRH-II-induced [Ca2+]i increase. Concurrently at high concentrations, trptorelix-1 and cetrorelix inhibited GnRH-I-induced [Ca2+]i increase, whereas at low concentrations they exerted an agonistic action, inducing Ca2+ influx. High concentrations of trptorelix-1 but not cetrorelix-induced prostate cancer cell death, probably through an apoptotic process. Using photoaffinity labeling with 125I-[azidobenzoyl-D-Lys6]GnRH-II, we observed that an 80-kDa protein specifically bound to GnRH-II.

Conclusions: This study suggests the existence of a novel GnRH-II binding protein, in addition to a conventional GnRH-I receptor, in prostate cancer cells. These data may facilitate the development of innovatory therapeutic drugs for the treatment of prostate cancer.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
S Darby, J Stockley, M M Khan, C N Robson, H Y Leung, and V J Gnanapragasam
Expression of GnRH type II is regulated by the androgen receptor in prostate cancer
Endocr. Relat. Cancer, September 1, 2007; 14(3): 613 - 624.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Fister, A. R. Gunthert, G. Emons, and C. Grundker
Gonadotropin-Releasing Hormone Type II Antagonists Induce Apoptotic Cell Death in Human Endometrial and Ovarian Cancer Cells In vitro and In vivo
Cancer Res., February 15, 2007; 67(4): 1750 - 1756.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society